Cosette Pharma’s RYANODEX® (dantrolene sodium) for Injectable Suspension, Fully Stocked and Available

Cosette Pharmaceuticals is maintaining full availability of RYANODEX injectable suspension for healthcare providers in the United States and international markets.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/10/2026 - 08:00 AM EST

– – Following its acquisition from Eagle Pharmaceuticals and successful supply chain transition, Cosette maintains robust inventory to serve healthcare providers in the U.S. and international markets – –

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cosette Pharmaceuticals, Inc. ("Cosette"), a U.S.-based specialty pharmaceutical company, is maintaining full availability of RYANODEX^® (dantrolene sodium) for injectable suspension in the United States and international markets. Following its June 2026 acquisition of RYANODEX^® from Eagle Pharmaceuticals, and successful supply chain transition, Cosette is leveraging its established manufacturing and distribution capabilities to maintain a dependable supply of this critical treatment option for healthcare providers.

"Our acquisition of RYANODEX^® reflects Cosette's commitment to expanding access to important medicines and ensuring the infrastructure is in place to support them," said Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals. "Our ability to successfully integrate RYANODEX^® and ensure a dependable supply demonstrates the strength of our organization and our focus on delivering for healthcare providers and patients."

"Healthcare providers depend on having the medicines they need, when they need them," said Brad Leonard, Vice President, Commercial Operations at Cosette Pharmaceuticals. "Our priority is to ensure hospitals and healthcare providers have dependable access to RYANODEX^®, so they can focus on what matters most: delivering timely care to patients."

Please see the full Prescribing Information for RYANODEX^®. For more information, visit www.RYANODEX.com

About Cosette Pharmaceuticals

Cosette Pharmaceuticals, Inc. is a U.S.-based, leading specialty pharmaceutical company providing some of the most trusted and well-known brands in medicine — developing, manufacturing, and delivering products that make a difference in patients’ lives. Cosette’s strong growth has been driven by its proven ability to maximize the value of its portfolio through best-in-class marketing, promotion, and strategic distribution capabilities, enabling the company to scale efficiently while continuing to invest in high-quality, patient-centered therapies. Cosette has corporate headquarters in Bridgewater, New Jersey and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE). For more information, please visit www.cosettepharma.com or follow Cosette on LinkedIn.